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Abstract
Background: Preoperative liver stiffness (LS) measurement using transient elastography (TE) is useful for predicting late
recurrence after curative resection of hepatocellular carcinoma (HCC). We developed and validated a novel LS value-based
predictive model for late recurrence of HCC.
Methods: Patients who were due to undergo curative resection of HCC between August 2006 and January 2010 were
prospectively enrolled and TE was performed prior to operations by study protocol. The predictive model of late recurrence
was constructed based on a multiple logistic regression model. Discrimination and calibration were used to validate the
model.
Results: Among a total of 139 patients who were finally analyzed, late recurrence occurred in 44 patients, with a median
follow-up of 24.5 months (range, 12.4–68.1). We developed a predictive model for late recurrence of HCC using LS value,
activity grade II-III, presence of multiple tumors, and indocyanine green retention rate at 15 min (ICG R15), which showed
fairly good discrimination capability with an area under the receiver operating characteristic curve (AUROC) of 0.724 (95%
confidence intervals [CIs], 0.632–0.816). In the validation, using a bootstrap method to assess discrimination, the AUROC
remained largely unchanged between iterations, with an average AUROC of 0.722 (95% CIs, 0.718–0.724). When we plotted
a calibration chart for predicted and observed risk of late recurrence, the predicted risk of late recurrence correlated well
with observed risk, with a correlation coefficient of 0.873 (P,0.001).
Conclusion: A simple LS value-based predictive model could estimate the risk of late recurrence in patients who underwent
curative resection of HCC.
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Introduction
Hepatic resection is the treatment of choice for hepatocellular
carcinoma (HCC) in non-cirrhotic patients and remains the
mainstay of treatment in cirrhotic patient with well-preserved liver
function.[1] Although adequate patient selection, optimized
surgical technique and postoperative management increased
treatment efficacy, recurrence remains the main cause of a
unsatisfactory long-term prognosis rate after resection of HCC.[2]
Thus, identifying risk factors for recurrence after curative resection
is important when selecting optimal candidates for resection and
predicting a postoperative prognosis.
As recent study revealed that the prognosis and underlying
mechanism are different for early and late recurrence, indepen-
dent risk factors for each type of recurrence have been investigated
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respectively.[2–5] Among these, advanced liver fibrosis or cirrhosis
is a known risk factor for late recurrence, as it contributes to
multicentric recurrence at the remnant liver.[2,3,6] Furthermore,
advanced liver fibrosis or cirrhosis is closely correlated with the
development of postoperative mortality or complications, such as
liver failure, worsening encephalopathy, or ascites.[7–9] Thus, a
preoperative assessment of liver fibrosis severity is essential for
prediction of postoperative outcomes.
Recently, liver stiffness (LS) measurement using transient
elastography (TE, FibroScan) has been used to assess the degree
of liver fibrosis noninvasively with high reproducibility and
reliability.[10,11] After much research into the role of LS value
in predicting future development of clinical endpoints such as
hepatic decompensation or HCC[12–14], several studies revealed
that preoperative LS value could be used in the preoperative
setting to predict postoperative outcomes such as hepatic
insufficiency or operative blood loss.[7,15] Furthermore, a recent
study demonstrated that preoperative LS value was significantly
correlated with intrahepatic recurrence after curative resection of
HCC, particularly with late recurrence, suggesting that LS value
could be used to stratify the risk of recurrence in patients with a
remnant fibrotic liver.[16]
Thus, this prospective study was designed to investigate the
correlation of LS value with the risk of late recurrence of HCC,
and if such a correlation was identified, to construct and validate a
LS value-based predictive model for late recurrence in patients
who underwent curative resection of HCC.
Materials and Methods
Predictive model derivation
Between August 2006 and January 2010, patients with HCC,
who were due to undergo curative resection of HCC at Severance
Hospital, Yonsei University College of Medicine, Seoul, Korea,
were prospectively enrolled in this study. Inclusion criteria were as
follows; (1) age .20 years, (2) volunteered to participate in the
study, (3) no previous diagnosis or treatment for HCC. TE was
performed after enrollment to obtain preoperative LS value within
1 month prior to the operation by study protocol.
The database of our cohort included information on patient
demographics, preoperative laboratory results, preoperative LS
values, and pathological results of extracted liver and HCC
specimens. The study protocol was consistent with the ethical
guidelines of the 1975 Declaration of Helsinki. Written informed
consent was obtained from each participant. This study was
approved by the Ethics Committee/Independent Institutional
Review Board of Severance Hospital, Yonsei University College of
Medicine, Seoul, Korea.
Diagnosis of HCC
The preoperative diagnosis of HCC was made based on
dynamic imaging studies, biopsy, and alpha-fetoprotein (AFP)
serology according to the AASLD guideline.[17] Before surgery,
the size, number, and location of HCC, and the presence of
extrahepatic metastatic lesions were confirmed by imaging studies
including computed tomography (CT), magnetic resonance
imaging (MRI), positron emission tomography, and angiography.
Preoperative LS measurement
The principles of LS measurement have been described
previously.[10] Briefly, TE generates an elastic wave using a
vibrator ultrasound transducer applied to the intercostal spaces at
the level of the right lobe of the liver and measures the propagation
velocity of the shear wave, which is directly related to LS. LS
values were obtained according to the instructions provided by the
manufacturer. Immediately after ultrasonographic evaluation of
the right hepatic lobe to avoid interference by HCC, LS
measurement was performed on the right lobe of the liver through
the intercostal spaces on patients lying in the dorsal decubitus
position with the right arm in maximal abduction. A single
experienced technician (more than 10,000 examinations), who was
blind to the patients’ clinical data, performed TE. The results were
expressed as kilopascals (kPa).
Before surgery, TE was performed once at a single visit and LS
values were measured more than 10 times during a single
performance of TE. The interquartile range (IQR) was defined as
an index of intrinsic variability of LS values corresponding to the
interval of LS value containing 50% of the valid measurements
between the 25th and 75th percentiles. The median value of
successful measurements was selected as representative of the LS
values in a given patient. Only LS values with at least 10 validated
measurements, an IQR to median value ratio (IQR/M) of ,0.3,
and a success rate of at least 60% were considered reliable. LS
value that did not satisfy these conditions was considered
unreliable and excluded from further analysis.
Surgery and follow-up
The time of surgery was determined after diagnostic work up of
HCC considering the status of the patient and the operation
schedule. All resections were performed by three experienced
surgeons (GH Choi, KS Kim, and JS Choi). The type and extent
of resection were determined according to tumor size, location,
and liver reserve function estimated by the Child-Pugh score and
indocyanine green retention rate at 15 min (ICG R15).[18]
Intraoperative ultrasonography was performed routinely to
determine tumor location and extent and to exclude the presence
of additional lesions in the residual liver. Curative resection was
defined as a negative histopathological surgical margin and the
absence of residual tumor, as demonstrated by abdominal CT
scans 1 month after hepatectomy.
Patients were followed up 1 month after surgery and every 3
months thereafter with tumor markers (AFP and des-gamma
carboxy prothrombin) and imaging studies including abdominal
CT or MRI. Recurrence was diagnosed based on the combined
findings of these clinical examinations, and sub-classified as early
(,1 year) and late ($1 year) recurrence [3,19].
Histological evaluation of extracted liver specimens
A histological evaluation of the extracted liver specimens was
performed by one experienced hepatopathologist (YN Park) who
was blind to the patients’ clinical information. Gross tumor
classification, tumor size and number, tumor capsule formation
and invasion, macroscopic or microscopic vascular invasion,
satellite nodule, and the Edmondson-Steiner grade were deter-
mined.[20,21] All HCCs were histologically confirmed in 139
patients and tumor stage was determined using the tumor, node,
metastasis (TNM) staging system of the American Joint Commis-
sion on Cancer (7th edition).[22] _ENREF_20_ENREF_20Liver
fibrosis and necroinflammatory activity were evaluated semi-
quantitatively in non-cancerous tissues according to the Metavir
system.[23] Fibrosis was staged on a 0–4 scale: F0, no fibrosis; F1,
portal fibrosis without septa; F2, portal fibrosis and a few septa; F3,
numerous septa without cirrhosis and F4, cirrhosis. Histological
activity grade (degree of necroinflammatory activity in the lobules
and periportal area) was scored as follows: A0, no activity; A1,
mild activity; A2, moderate activity and A3, severe activity.
Activity grade was defined as lobule or periportal activity
(whichever was higher) [23].
Liver Stiffness Value-Based Model for Recurrence
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Statistical analyses
Data are expressed as means 6 standard deviation (SD),
medians (range), or n (%), as appropriate. Comparisons between
patients with late recurrence and those without were performed
using Student’s t-test or the Mann-Whitney test for continuous
variables and the chi-square or Fisher’s exact tests for categorical
variables. In a univariate analysis, patient demographics including
background liver etiology, preoperative laboratory results includ-
ing ICG R15, preoperative LS values, surgical factors (types and
extent of resections, resection margin, intraoperative blood loss,
and perioperative transfusion) and pathological results of the
extracted liver (fibrosis and necroinflammatory activity) and HCC
(gross tumor classification, tumor size and number, tumor capsule
formation and invasion, macroscopic or microscopic vascular
invasion, satellite nodule, and the Edmondson-Steiner grade) were
evaluated in terms of their relationship with late recurrence. Based
on variables with clinical relevance and a univariate statistical
significance, multivariate predictive model was constructed using a
logistic regression model. The output of the model was expressed
as regression coefficients, odd ratios (ORs), and 95% confidence
intervals (CIs), which were used to predict late recurrence of HCC.
The model was validated by discrimination and calibration.
Discrimination was assessed with the receiver operating charac-
teristic curve, area under the receiver operating characteristic
curve (AUROC), sensitivity, and specificity. We calculated the
predicted risk of late recurrence based on our predictive model
and then estimated the observed risk of late recurrence to assess
calibration. Observed risk estimates were plotted against the
predicted risk in the group to create a calibration chart. All
statistical analyses were conducted using the SAS software, ver. 9.2
(SAS Institute, Cary, NC, USA).
Results
Baseline characteristics
A total of 164 patients with HCC who underwent curative
resection of HCC were enrolled. Five patients were excluded due
to LS measurement failure (no valid shot) or an unreliable LS
value. Thereafter, since the purpose of our study was to investigate
the risk factor and construct a model to predict late recurrence of
HCC, two patients with perioperative mortality (death within 1
month of the operation) and 18 with early recurrence (,1 year)
were also excluded from the analysis (Fig. 1). Finally, the study
cohort consisted of 139 patients, who were used to develop the
predictive model for late recurrence after curative resection. With
exception of 16 patients who died during study period due to
recurrence, the patients were followed-up until October 2012, and
the median follow-up period was 42.9 months (range, 20.4–72.7
months).
The baseline characteristics of the study population are
summarized in Table 1. Median age (119 males and 20 females)
was 59 years. The most common etiology of underlying liver
disease was chronic hepatitis B (n= 113, 81.3%). Liver cirrhosis
was histologically confirmed in 56 (40.3%) patients. Median tumor
size was 3.0 cm, and most tumors (n = 118, 84.9%) were single.
According to the TNM staging system, 84 (60.5%) patients were
classified as stage I, 7 (5.0%) stage II, and 48 (34.5%) stage IIIA.
Late recurrence was observed in 44 (31.7%) patients at a
median of 24.5 months (range, 12.4–68.1 months). Intrahepatic
recurrence was identified in all patients with late recurrence.
Among these patients, simultaneous extrahepatic metastasis with
intrahepatic recurrence were identified in seven patients at the
time of recurrence (lung, n = 4; bone, n= 3).
LS values and the performance to predict liver fibrosis
LS value using TE was obtained for all patients within 1 month
before surgery (median 5 days; range 1–30 days). The median LS
value was 10.5 kPa (range, 4.0–45.0 kPa). LS values according to
fibrosis stage were 5.1 kPa for F0-1 (range, 4.1–5.5 kPa), 8.5 kPa
for F2 (range, 4.0–35.3 kPa), 9.2 kPa for F3 (range, 4.1–38.0 kPa),
and 13.4 kPa for F4 (range, 5.8–45.0 kPa) (Fig. 2). The median
LS value increased significantly with fibrosis stage (all P,0.05).
The AUROCs of LS values to predict $F2, $F3, and F4 were
0.951 (95% CI, 0.913–0.988), 0.796 (95% CI, 0.702–0.889), and
0.837 (95% CI, 0.755–0.919), respectively.
Multivariate logistic regression model
The influence of each variable was tested in a univariate analysis
(Table S1). In our cohort, ICG R15, the presence of multiple
tumors, activity grade II-III, and LS value were significantly
related with late recurrence in the univariate analysis (all P,0.05),
whereas other variables were not statistically significant. A
multivariate analysis was performed using the variables that
exhibited statistical significance in the univariate analysis. Table 2
shows the b-regression coefficient estimates in the multivariate
logistic regression model. In the multivariate analysis, activity
grade II-III, and LS value were identified as independent
predictors of late recurrence (all P,0.05), whereas ICG R-15
and the presence of multiple tumors did not achieve statistical
significance (P.0.05).
Development of a predictive model of late HCC
recurrence
In addition to the two independent variables (activity grade II-
III, and LS value), ICG R-15 and the presence of multiple tumors
were also incorporated as constituent variables to develop a
predictive model for late HCC recurrence, which is a known
significant risk factor for late recurrence.[24,25] This predictive
model showed a fairly good discrimination capability, with an
AUROC of 0.724 (95% CIs, 0.632–0.816).
Probability of recurrence~
exp ({2:9733z0:0616|Az1:2470|Bz0:3750|C
z0:0213|D)
7(1z exp ({2:9733z0:0616|Az1:2470|Bz0:3750|C
z0:0213|D))
Where A=LS value (kPa); B = activity grade II-III (0: no, 1: yes);
C=multiple tumors (0: no, 1: yes); D= ICGR15 (%)
Discrimination and calibration
We used a bootstrap method to assess discrimination, in which
1,000 random samples were drawn with replacement from the
original dataset, and AUROCs were recalculated in each sample.
The AUROCs remained largely unchanged between iterations,
with an average AUROC of 0.722 (95% CIs, 0.718–0.724). We
plotted a calibration chart that compared the predicted and
observed risks of late HCC recurrence (Fig. 3). The predicted risk
of late recurrence calibrated well with the observed risk, with a
correlation coefficient of 0.873(P,0.001).
Discussion
Although the risk factors for postoperative recurrence have been
investigated extensively, few mathematical models are available to
Liver Stiffness Value-Based Model for Recurrence
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Figure 1. Flow chart of patient selection. A total of 164 patients with HCC undergoing curative resection were recruited. Five patients were
excluded due to LS measurement failure or an unreliable LS measurement. Of the 159 patients with a reliable LS value, 20 were excluded due to
postoperative death within 1 month, or early recurrence within 1 year. Thus, a total of 139 patients were selected for statistical analysis. HCC,
hepatocellular carcinoma; LS, liver stiffness measurement.
doi:10.1371/journal.pone.0099167.g001
Table 1. Baseline characteristics (n = 139).
Variable
Host factors
Age (years) 59 (32–80)
Male 119 (85.6)
Body mass index (kg/m2) 23.3 (15.9–32.5)
Etiology, HBV/HCV/non-B non-C 113 (81.3)/11 (7.9)/15 (10.8)
Total bilirubin (mg/dL) 0.760.2
Albumin (g/dL) 4.360.4
Prothrombin time (%) 93.167.6
Aspartate aminotransferase (IU/L) 35.5617.9
Alanine aminotransferase (IU/L) 40.0630.1
Alpha-fetoprotein (ng/mL) 24.4 (1–83,000)
Des-gamma carboxy prothrombin (mAU/mL) 56.0 (5–2,000)
Indocyanine green retention rate at 15 min (%) 8.5 (1.0–31.2)
Tumor factors
Tumor size (cm) 3.0 (1.0–9.5)
Tumor number, single/multiple 118 (84.9)/21 (15.1)
Tumor stage, I/II/IIIA 84 (60.4)/7 (5.0)/48 (34.5)
Portal vein invasion 9 (6.5)
Satellite nodule 3 (2.2)
Edmonson-Steiner grade, I-II, III-IV 97 (69.8)/42 (30.2)
Non-tumor liver pathology
F0-1/F2/F3/F4 5 (3.6)/44 (31.7)/34 (24.5)/56 (40.3)
A1/A2/A3 47 (33.8)/89 (64.0)/3 (2.2)
Liver stiffness measurement
Liver stiffness value (kPa) 10.5 (4.0–45.0)
Interquartile range (kPa) 1.6 (0.3–9.8)
Success rate (%) 97.0 (63–100)
Variables are expressed as median (range) or n (%).
HBV, hepatitis B virus; HCV, hepatitis C virus; kPa, kilopascal.
doi:10.1371/journal.pone.0099167.t001
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predict recurrence after resection of HCC. [26–29] As none of the
previous models included the effect of fibrosis in the formula, this is
the first study to validate a specified prediction model for late
recurrence of HCC based on LS value, which accurately reflects
the burden of liver fibrosis. Finally, this study demonstrated that
LS value-based predictive model could estimate the risk of late
recurrence in patients who have undergone curative resection of
HCC with considerable accuracy.
Compared to other risk factors, for a long time, the impact of
liver fibrosis on recurrence has generally been underestimated. In
previous studies, the influence of liver fibrosis was attenuated by
other risk factors such as pathological factors, because recurrence
was not classified into early and late one.[2,28,30] However, when
types of recurrence were considered in the analysis, advanced liver
fibrosis was selected as one of the independent risk factors for late
recurrence.[3,16,24,31] Additionally, as advances in surgical
technique and proper patient selection have reduced early
recurrence, which has a poorer prognosis than late recurrence,
the effect of underlying fibrosis on long-term prognosis has gained
greater importance. Despite its clinical importance, in most cases,
it is difficult to assess histological staging of liver fibrosis prior to
surgical resection. This suggests the need for a preoperative and
non-invasive method of estimating liver fibrosis for selecting
optimal candidates for resection or making individualized treat-
ment and follow-up plans.
Recently, it has been proposed that preoperative LS value
assessed using TE is significantly associated with recurrence,
suggesting that clinicians can estimate fibrosis status noninvasively
and accurately before surgery.[16] Consistently, preoperative LS
value was selected as independent risk factor for late recurrence in
this study, whereas histological fibrosis stage was not significant
even in a univariate analysis.[16] These results might suggest that
risk stratification using preoperative LS value could add more
prognostic information for patients undergoing resection regard-
less of the histological findings, as LS might enable more precise
quantification of liver fibrosis, expressed as continuous values, than
simple stepwise histological grading. These findings also support a
theoretical concept that the main mechanism of late recurrence is
de novo development of HCC from a remnant fibrotic liver, rather
than from dissemination of primary tumor cells [2].
Because the mechanism of late recurrence could not be
explained solely by liver fibrosis, we developed a prediction model
that included other important clinical factors and that could be
validated internally. At first, as necroinflammatory activity was
Figure 2. Distribution of LS values according to fibrosis stage. The median LS value increased significantly with fibrosis stage (P,0.001). LS,
liver stiffness.
doi:10.1371/journal.pone.0099167.g002
Table 2. Multivariate analysis to identify independent predictors ofHCC occurrence.
Factor Beta P value Odd ratios (95% CIs)
ICG R15 0.0213 0.5715 1.022 (0.949–1.100)
Multiple tumors 0.3750 0.4565 1.455 (0.542–3.904)
Activity grade II-III 1.2470 0.0121 3.480 (1.313–9.221)
Liver stiffness value 0.0616 0.0172 1.063 (1.011–1.119)
HCC, hepatocellular carcinoma; CIs, confidence intervals; ICG R15, Indocyanine green retention rate at 15 min (%).
doi:10.1371/journal.pone.0099167.t002
Liver Stiffness Value-Based Model for Recurrence
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significantly associated with late recurrence in the multivariate
analysis, consistent with previous studies, it was included in our
predicting model.[24,32,33] Because liver fibrosis and necroin-
flammation are associated with a risk of carcinogenesis, it may
enhance the performance to assess the risk of HCC development
by incorporating simultaneously LS value and necroinflammatory
activity into our prediction model.[4,17] _ENREF_17Neverthe-
less, there can be a concern regarding potential overestimation of
the influence of necroinflammation on LS values, which affected
the overall performance of our prediction model.[34,35] However,
because we did not detect a correlation between LS and
necroinflammatory activity in our patient cohort in a univariate
analysis (P.0.05 by Spearman’s correlation analysis), it was
possible to use these two variables which reflect the degree of
fibrosis and activity for our prediction model.
In addition, ICG R15, which had significant correlation with
late recurrence in a univariate analysis, was included in our
prediction model. Indeed, ICG R15 was significantly correlated
with late recurrence in previous studies.[4,24] _ENRE-
F_24Although ICG R15 has been used to estimate remnant liver
function after hepatectomy[18], the value of ICG R15 for
predicting late recurrence was attenuated in our cohort. However,
because ICG R15 could reflect the degree of functional liver status
by estimating hepatic metabolic capacity whereas LS values could
reflect the degree of physical status of liver fibrosis, we
incorporated ICG R15 in our prediction model based on the
hypothesis that the combination of these two parameters would
strengthen the accuracy of our prediction model. Lastly, the
presence of multiple tumors was included in our prediction
models. Previous studies have demonstrated that the presence of
multiple tumors was significantly related to late recurrence,
suggesting that tumor multiplicity reflects increased carcinogenic-
ity of the background liver.[2,4] In this study, the presence of
multiple tumors, which was confirmed histologically, was success-
fully diagnosed by radiological methods in all patients prior to
resection. This result suggests that an advanced imaging modality
can detect multiple tumors sensitively, thus the presence of
multiple tumors, which was assessed by preoperative imaging,
could be incorporated in the model.
Our new prediction model consisted of four variables: LS value,
activity grade, presence of multiple tumors, and ICG R15, but
other risk factors such as vascular invasion, tumor differentiation,
and preoperative AFP level were not included in our model.
Although these factors were identified as significant risk factors of
recurrence in previous studies[36,37], they did not achieve
significance, even in the univariate analysis in this study.
Additionally, because these factors did not enhance accuracy of
our model, they were excluded from our final prediction model.
Although our study proposed a LS values-based HCC
prediction model after curative resection, several issues remain
unresolved in our study. First, this prediction model was developed
using a relatively small sized cohort with various liver disease
etiologies and validated internally and its accuracy seemed modest
(AUROC=0.724). Although, the etiology of liver disease was not
significantly related to late recurrence in this study, consistently
with the results of previous studies (P.0.05), further research with
a larger and more homogenous study population should be
followed by external validation.[2] Second, cross-sectional meth-
ods of identifying the risk factors for late recurrence in a cohort
with variable follow-up time and exclusion of patients with early
recurrence might lead to a selection bias. However, because the
aim of our study was to develop a model to predict the risk of late
recurrence itself, not the increasing risk of late recurrence over
time, we used logistic regression instead of longitudinal statistical
methods. Additionally, a short follow-up time less than 3 years was
identified in 10 patients who died after recurrence and the
remaining patients (n = 129) were followed up more than 3 years,
suggesting that the current cross-sectional approach might be
adequate for our cohort to compensate for the wide range of
follow-up durations. Similar to our work, previous studies used
cross-sectional methods to identify the risk factors for the late
recurrence after resection of HCC.[3,38] However, additional
studies of a prediction model based on a survival analysis, such as
Cox-regression or standardization of follow-up time, are required
in the future. Third, as histological necroinflammatory activity
grade was included, our model cannot be used prior to resection.
Consequently, it does not seem feasible to use this model for
stratification of an appropriate treatment modality such as liver
transplantation, instead of surgical resection, especially for patients
at high risk of recurrence after resection. Thus, it will be important
to determine whether other noninvasive surrogate markers of the
degree of necroinflammatory activity grade may be used as a
preoperative risk calculator. Serum aminotransferase or apolipo-
protein A1 are possible candidates as they revealed a significant
correlation with necroinflammatory activity in a previous
study.[39] Lastly, this model did not include gene expression
profiles of surrounding non-cancerous liver tissue, which has been
emphasized in recent studies as a significant risk factor for late
recurrence after curative resection for HCC.[40,41] However,
from a different point of view, our results might suggest the
importance of the characteristics of the remnant liver, such as LS
values, ICG R15, and necroinflammation in predicting late
recurrence in patients who have undergone curative resection of
HCC.
In conclusion, this study constructed and validated a novel LS
value-based model for predicting late HCC recurrence. This
model, which involved tumor and non-tumor characteristics,
demonstrated acceptable accuracy in patients who underwent
curative resection of HCC. However, further studies with a larger
sample size are warranted for external validation of our prediction
model.
Figure 3. Calibration chart for predicted versus observed risk
of late recurrence after curative resection of HCC. The predicted
risk of recurrence calibrated well with the observed risk, with a
correlation coefficient of 0.873 (P,0.001).HCC, hepatocellular carcino-
ma.
doi:10.1371/journal.pone.0099167.g003
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